Literature DB >> 8182157

Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells.

A Bergamini1, M Capozzi, L Ghibelli, L Dini, A Salanitro, G Milanese, T Wagner, S Beninati, C D Pesce, C Amici.   

Abstract

We have investigated the effects of cystamine on the replication of human immunodeficiency virus (HIV) in human lymphocytes and macrophages, the natural targets of HIV in vivo. Treatment of chronically infected macrophages with cystamine, at a concentration (500 microM) that did not show any cytotoxic or cytostatic effects, strongly decreased (> 80%) HIV-p24 antigen production and completely abolished the production of infectious viral particles. Cystamine does not affect viral transcription, translation or protein processing; indeed, all HIV proteins are present in a pattern similar to that of nontreated cells. Instead, cystamine interferes with the orderly assembly of HIV virions, as shown by electron microscopy analysis, that reveals only defective viral particles in treated cells. Moreover, suppression of HIV replication, due to the inhibition of proviral DNA formation was observed in acutely infected lymphocytes and macrophages pretreated with cystamine. These results show that cystamine potently suppresses HIV replication in human cells by contemporaneously blocking at least two independent steps of the viral life cycle, without affecting cell viability, suggesting that this compound may represent a new possibility towards the treatment of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182157      PMCID: PMC294379          DOI: 10.1172/JCI117223

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus.

Authors:  F J Staal; M Roederer; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Infection of monocyte/macrophages by human T lymphotropic virus type III.

Authors:  D D Ho; T R Rota; M S Hirsch
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

3.  Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine.

Authors:  M Roederer; F J Staal; P A Raju; S W Ela; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  2,3 Dimercapto-1-propanol inhibits HIV-1 tat activity, viral production, and infectivity in vitro.

Authors:  S Kubota; M A el-Farrash; M Maki; S Harada; M Hatanaka
Journal:  AIDS Res Hum Retroviruses       Date:  1990-07       Impact factor: 2.205

Review 5.  Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection.

Authors:  M S Meltzer; D R Skillman; P J Gomatos; D C Kalter; H E Gendelman
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

6.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

7.  Protection by pantethine, pantothenic acid and cystamine against carbon tetrachloride-induced hepatotoxicity in the rat.

Authors:  I Nagiel-Ostaszewski; C A Lau-Cam
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1990-02

8.  Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction.

Authors:  H E Gendelman; L M Baca; J Turpin; D C Kalter; B Hansen; J M Orenstein; C W Dieffenbach; R M Friedman; M S Meltzer
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

9.  A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes.

Authors:  H E Gendelman; R M Friedman; S Joe; L M Baca; J A Turpin; G Dveksler; M S Meltzer; C Dieffenbach
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

10.  Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies.

Authors:  C F Perno; M W Baseler; S Broder; R Yarchoan
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

View more
  5 in total

1.  HIV-1 does not alter in vitro and in vivo IL-10 production by human monocytes and macrophages.

Authors:  A Bergamini; F Bolacchi; E Faggioli; R Placido; S Vendetti; L Cappannoli; L Ventura; G Cerasari; I Uccella; M Andreoni; G Rocchi
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

2.  L-2-oxothiazolidine-4-carboxylic acid inhibits human immunodeficiency virus type 1 replication in mononuclear phagocytes and lymphocytes.

Authors:  W Z Ho; S E Starr; A Sison; S D Douglas
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

3.  WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.

Authors:  Dale M Walker; Adriana E Kajon; Salina M Torres; Meghan M Carter; Consuelo L McCash; James A Swenberg; Patricia B Upton; Andrew W Hardy; Ofelia A Olivero; Gene M Shearer; Miriam C Poirier; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-07       Impact factor: 3.216

Review 4.  Thiosulfoxide (sulfane) sulfur: new chemistry and new regulatory roles in biology.

Authors:  John I Toohey; Arthur J L Cooper
Journal:  Molecules       Date:  2014-08-21       Impact factor: 4.411

5.  Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection.

Authors:  Douglas J Fraser-Pitt; Derry K Mercer; Daniel Smith; Aleksandra Kowalczuk; Jennifer Robertson; Emma Lovie; Peter Perenyi; Michelle Cole; Michel Doumith; Robert L R Hill; Katie L Hopkins; Neil Woodford; Deborah A O'Neil
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.